Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Merck
Deloitte
UBS
Dow
Julphar
Cerilliant
Cipla

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,435,745

« Back to Dashboard

Summary for Patent: 7,435,745
Title:Methods and compositions for inhibition of angiogenesis
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert J. (Cambridge, MA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:11/411,230
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,435,745

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,435,745

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 305301 ➤ Try a Free Trial
Austria 405268 ➤ Try a Free Trial
Austria 493983 ➤ Try a Free Trial
Australia 2005202596 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Dow
Mallinckrodt
US Army
US Department of Justice
QuintilesIMS
Cerilliant
Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.